Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

FDA Grants Orphan Drug Designation For IDEAYA's Darovasertib For Uveal Melanoma

The U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to IDEAYA Biosciences (NASDAQ:IDYA) for its drug candidate Darovasertib for the treatment of uveal melanoma.

Darovasertib in combination with Crizotinib is being evaluated in an ongoing Phase 1/2 clinical trial in patients with metastatic uveal melanoma (MUM) and in patients with GNAQ or GNA11 mutant solid tumors.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.